Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-142 malaria vaccine

Molecular and Biochemical Parasitology

Volumn 128, Issue 2, 2003, Pages 195-204

  Angov, Evelina ^a   Aufiero, Barbara M ^a   Turgeon, Ann Marie ^a   Van Handenhove, Michel ^b   Ockenhouse, Christian F ^a   Kester, Kent E ^a   Walsh, Douglas S ^c   McBride, Jana S ^d   Dubois, Marie Claude ^b   Cohen, Joe ^b   Haynes, J David ^a   Eckels, Kenneth H ^a   Heppner, D Gray ^a   Ballou, W Ripley ^a   Diggs, Carter L ^e   Lyon, Jeffrey A ^a  

^a WRAIR   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

Author keywords

Adjuvant; Alum; AS02A; Erythrocyte; Falciparum; Growth inhibition; Immunogenicity; Malaria; Merozoite Surface Protein 1; MSP 1; Process development; Processing inhibition; Protein; Purification; Safety; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ENDOTOXIN; FREUND ADJUVANT; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MONOCLONAL ANTIBODY; RESIN;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN PURIFICATION; ARTICLE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG EFFECT; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; ESCHERICHIA COLI; FEMALE; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GROWTH INHIBITION; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; MALARIA; MICROBIAL GROWTH; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RABBIT; RHESUS MONKEY; SEROCONVERSION; VACCINATION;

ESCHERICHIA COLI; MACACA; MACACA MULATTA; ORYCTOLAGUS CUNICULUS; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0038665176     PISSN: 01666851     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-6851(03)00077-X     Document Type: Article

References (37)

1. World Health Organization. World malaria situation in 1994. Wkly Epidemiol Rec 1997;72:269-76.
2. Cohen S., McGregor I.A., Carrington S. Gamma globulin and acquired immunity to malaria. Nature. 192:1964;733-737.
3. Diggs C.L., Ballou W.R., Miller L.H. The major merozoite surface protein as malaria vaccine target. Parasitol. Today. 9:1993;300-302.
4. Haldar K., Ferguson M.A., Cross G.A. Acylation of a Plasmodium falciparum merozoite surface antigen via sn-1,2-diacylglycerol. J. Biol. Chem. 260:1985;4969-4974.
5. Holder A.A., Freeman R.R. Protective antigens of rodent and human bloodstage malaria. Phil. Trans. R. Soc. Lond. B. Biol. Sci. 307:1984;171-177.
6. Lyon J.A., Haynes J.D., Diggs C.L., Chulay J.D., Haidaris C.G., Pratt-Rossiter J. Monoclonal antibody characterization of the 195-kDa major surface glycoprotein of Plasmodium falciparum malaria schizonts and merozoites: identification of additional processed products and a serotype-restricted repetitive epitope. J. Immunol. 138:1987;895-901.
7. Holder A.A., Sandhu J.S., Hillman Y., Davey L.S., Nicholls S.C., Cooper H.et al. Processing of the precursor to the major merozoite surface antigens of Plasmodium falciparum. Parasitology. 94:1987;199-208.
8. Blackman M.J., Ling I.T., Nicholls S.C., Holder A.A. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol. Biochem. Parasitol. 49:1991;29-33.
9. Blackman M.J., Holder A.A. Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol. Biochem. Parasitol. 50:1992;307-315.
10. Morgan W.D., Birdsall B., Frenkiel T.A., Gradwell M.G., Burghaus P.A., Syed S.E.et al. Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. J. Mol. Biol. 289:1999;113-122.
11. Farley P.J., Long C.A. Plasmodium yoelii yoelii 17XL MSP-1: fine-specificity mapping of a discontinuous, disulfide-dependent epitope recognized by a protective monoclonal antibody using expression PCR (E-PCR). Exp. Parasitol. 80:1995;328-332.
12. McBride J.S., Heidrich H.G. Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex. Mol. Biochem. Parasitol. 23:1987;71-84.
13. Uthaipibull C., Aufiero B., Syed S.E., Hansen B., Guevara Patino J.A., Angov E.et al. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 307:2001;1381-1394.
14. Perkins M.E., Rocco L.J. Sialic acid-dependent binding of Plasmodium falciparum merozoite surface antigen, Pf200, to human erythrocytes. J. Immunol. 141:1988;3190-3196.
15. Holder A.A. Proteins on the surface of the malaria parasite and cell invasion. Parasitology. 108:1994;S5-S18.
16. Blackman M.J., Heidrich H.G., Donachie S., McBride J.S., Holder A.A. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J. Exp. Med. 172:1990;379-382.
17. Majarian W.R., Daly T.M., Weidanz W.P., Long C.A. Passive immunization against murine malaria with an IgG3 monoclonal antibody. J. Immunol. 132:1984;3131-3137.
18. Ling I.T., Ogun S.A., Holder A.A. Immunization against malaria with a recombinant protein. Parasite Immunol. 16:1994;63-67.
19. Siddiqui W.A., Tam L.Q., Kramer K.J., Hui G.S., Case S.E., Yamaga K.M.et al. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. U.S.A. 84:1987;3014-3018.
20. Chang S.P., Case S.E., Gosnell W.L., Hashimoto A., Kramer K.J., Tam L.Q.et al. A recombinant baculovirus 42-kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect. Immun. 64:1996;253-261.
21. Kumar S., Yadava A., Keister D.B., Tian J.H., Ohl M., Perdue-Greenfield K.A.et al. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol. Med. 1:1995;325-332.
22. Burns J.M. Jr., Majarian W.R., Young J.F., Daly T.M., Long C.A. A protective monoclonal antibody recognizes an epitope in the carboxyl-terminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite, Plasmodium yoelii. J. Immunol. 143:1989;2670-2676.
23. Chang S.P., Gibson H.L., Lee-Ng C.T., Barr P.J., Hui G.S. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J. Immunol. 149:1992;548-555.
24. Gozalo A., Lucas C., Cachay M., Wellde B.T., Hall T., Bell B.et al. Passive transfer of growth-inhibitory antibodies raised against yeast-expressed recombinant Plasmodium falciparum merozoite surface protein-1(19). Am. J. Trop. Med. Hyg. 59:1998;991-997.
25. Quin S.J., Seixas E.M., Cross C.A., Berg M., Lindo V., Stockinger B.et al. Low CD4(+) T cell responses to the C-terminal region of the malaria merozoite surface protein-1 may be attributed to processing within distinct MHC class II pathways. Eur. J. Immunol. 31:2001;72-81.
26. Quin S.J., Langhorne J. Different regions of the malaria merozoite surface protein 1 of Plasmodium chabaudi elicit distinct T-cell and antibody isotype responses. Infect. Immun. 69:2001;2245-2251.
27. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor Laboratory Press; 1989.
28. Hall R., McBride J., Morgan G., Tait A., Zolg J.W., Walliker D.et al. Antigens of the erythrocytes stages of the human malaria parasite Plasmodium falciparum detected by monoclonal antibodies. Mol. Biochem. Parasitol. 7:1983;247-265.
29. Chang S.P., Kramer K.J., Yamaga K.M., Kato A., Case S.E., Siddiqui W.A. Plasmodium falciparum: gene structure and hydropathy profile of the major merozoite surface antigen (gp195) of the Uganda-Palo Alto isolate. Exp. Parasitol. 67:1988;1-11.
30. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P.et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTSS Malaria Vaccine Evaluation Group. New Engl. J. Med. 336:1997;86-91.
31. Haynes J.D., Moch J.K., Smoot D.S. Erythrocytic malaria growth or invasion inhibition assays with emphasis on suspension culture GIA. Methods Mol. Med. 72:2002;535-554.
32. Blackman M.J. Purification of Plasmodium falciparum merozoites for analysis of the processing of merozoite surface protein-1. Methods Cell Biol. 45:1994;213-220.
33. Egan A.F., Morris J., Barnish G., Allen S., Greenwood B.M., Kaslow D.C.et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J. Infect. Dis. 173:1996;765-769.
34. Burghaus P.A., Holder A.A. Expression of the 19-kDa carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol. Biochem. Parasitol. 64:1994;165-169.
35. Guevara Patino J.A., Holder A.A., McBride J.S., Blackman M.J. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J. Exp. Med. 186:1997;1689-1699.
36. Chappel J.A., Holder A.A. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1. Mol. Biochem. Parasitol. 60:1993;303-311.
37. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T.et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183:2001;640-647.